Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

ChronoScale to divest Ekso Bionics operations

PUBLIC · CHRNAug 27, 2026about 4 hours ago

Acquiring Company

ChronoScale

Acquired Company

Ekso Bionics

San RafaelSoftwareArtificial IntelligenceMachine LearningManufacturingBiotechnologyHealth CareMedical Device

Description

ChronoScale, after a reverse merger, has decided to divest its subsidiary, Ekso Bionics Inc. The company aims to concentrate on its cloud business while navigating the sale of its worn robotics division. The divestiture is expected to occur in the first fiscal quarter ending in August.

Company Information

Company

ChronoScale

About

ChronoScale is an accelerated compute platform purpose-built to support demanding artificial intelligence workloads. Focused on large-scale deployments, the platform delivers dedicated compute environments optimized for performance, consistency, and scalability. Its products serve various markets that require AI training, inference, and high-performance computing.

Don't miss ChronoScale's next move

Get an email the moment ChronoScale makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Alma
Senior decision-maker at this company
••••••••@••••••••

See Alma's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for ChronoScale's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Ekso Bionics?

Ekso Bionics was acquired by ChronoScale. The deal was reported on August 27, 2026. ChronoScale is an accelerated compute platform purpose-built to support demanding artificial intelligence workloads. ChronoScale is publicly traded (CHRN) and operates in Software.

When did ChronoScale acquire Ekso Bionics?

ChronoScale's acquisition of Ekso Bionics was reported on August 27, 2026. ChronoScale, after a reverse merger, has decided to divest its subsidiary, Ekso Bionics Inc. The company aims to concentrate on its cloud business while navigating the sale of its worn robotics division. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Ekso Bionics do?

Ekso Bionics Inc. specializes in powered exoskeletons for rehabilitation and personal mobility. Their products are geared towards assisting patients with serious mobility challenges. It is publicly traded (CHRN), operating in Manufacturing, and is based in San Rafael.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.